Myriad Genetics partners with Epic to make genetic testing more accessible to more patients by integrating electronic health records (EHR)

Myriad Genetics, Inc.

Myriad Genetics, Inc.

  • Healthcare suppliers can simply order Myriad genetic assessments for greater than 250 million sufferers inside the Epic . community

  • Partnership advances Myriad’s development plan to increase customer-centric, technology-enabled enterprise capabilities with greater than 600 human digital information integrations this yr

Salt Lake Metropolis, June 23, 2022 (Globe Newswire) – Myriad Genetics, Inc.. (NASDAQ: MYGN), the chief in genetic testing and precision drugs, right now introduced a partnership with Epic, the industry-leading healthcare software program firm, to combine Myriad’s full suite of genetic testing with Epic’s increasing community of 600,000 physicians and greater than 250 million sufferers. .

The mixing creates a seamless, end-to-end workflow answer for healthcare suppliers to request Myriad assessments and overview outcomes immediately inside their each day Epic platform with out extra steps or handbook ordering processes. Epic allows the safe alternate of knowledge between healthcare organizations that look after sufferers.

With the power to overview related well being data, order assessments, and obtain outcomes regionally at Epic, suppliers may have the essential genetic insights and associated data they should obtain higher well being outcomes and enhance affected person expertise. Sufferers can even be capable to simply entry Myriad check outcomes and different well being data immediately by means of their EHR portal.

“Simplifying the genetic testing course of by making it extra intuitive and interoperable with digital well being information is a vital part of our mission to advance the well being and well-being of all,” mentioned Paul J. Diaz, President and CEO of Myriad Genetics. “Our collaboration with Epic displays our technique of partnering with different healthcare {industry} leaders in order that we are able to advance precision drugs collectively. Rising entry to genetic insights and integrating our assessments into Epic’s huge community of healthcare techniques is a crucial step ahead to raised serve sufferers and healthcare suppliers.”

As a part of its transformation and development plan, Myriad is specializing in new customer-centric and technology-enabled instruments to facilitate the genetic testing course of for sufferers and clinicians. With the current launch of Myriad’s Exact Oncology Options, suppliers can now submit a single request for numerous assessments and get leads to a well timed method by means of a unified on-line portal. Now, by partnering with Epic, Myriad is increasing its efforts to assist clinicians and well being techniques entry genetic testing sooner and extra conveniently inside the platform they use on daily basis.

“Genetic testing and precision drugs are saving lives,” mentioned Alan Hutchison, vp of inhabitants well being at Epic. “By means of this relationship, we convey genetic insights to the purpose of care at scale, offering suppliers and sufferers with the data they should make knowledgeable and well timed selections.”

Myriad’s integration with Epic is anticipated to start later this yr.

About Numerous Genetics
Myriad Genetics is a number one genetic testing and precision drugs firm devoted to advancing the well being and well-being of all. Myriad develops and commercializes genetic assessments that assist assess the chance of illness development or illness development and information remedy selections throughout medical specialties the place genetic insights can dramatically enhance affected person care and decrease well being care prices. Quick Firm named Myriad amongst Probably the most revolutionary corporations on the planet for 2022. For extra data, go to

Myriad, Brand Myriad, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, MyRisk MyRisk, MyRisk Hereditary Most cancers, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, PreciseI, FirstGene, Well being. . GeneSight and EndoPredict are emblems or registered emblems of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. all rights are save.

Protected Harbor Assertion
This press launch accommodates “forward-looking statements” inside the that means of the Personal Securities Litigation Reform Act of 1995, together with statements relating to the Firm’s merger of genetic testing with the Epic community of physicians and sufferers and the anticipated timing of the merger; The corporate’s development plan to increase customer-centric, technology-enabled enterprise capabilities with greater than 600 digital information integrations this yr; Anticipated advantages from the mixing, together with that the mixing will create a complete workflow answer for healthcare suppliers to order numerous assessments and overview outcomes immediately with their each day Epic workflows, offering suppliers with vital genetic insights and related data they should obtain wholesome outcomes Higher and improved affected person expertise, permitting sufferers to simply entry their Myriad check outcomes immediately from their EHR portal; and the corporate’s strategic imperatives underneath the title “About Myriad Genetics”. These “forward-looking statements” are administration’s present expectations of future occasions and are topic to numerous dangers and uncertainties that would trigger precise outcomes to vary materially and adversely from these proven within the forward-looking statements. These dangers embody, however aren’t restricted to: the uncertainties related to COVID-19, together with its potential results on the Firm’s operations, the demand for its services and products, and the Firm’s capability to function its enterprise effectively and flexibly; The danger that gross sales and revenue margins will decline for the corporate’s present molecular diagnostics assessments or that the corporate could not be capable to run its enterprise on a worthwhile foundation; Dangers associated to the Firm’s capability to generate enough income from its present product portfolio or in launching and advertising and marketing new assessments; Dangers associated to adjustments in state or personal insurers’ protection and reimbursement ranges for the Firm’s assessments or the Firm’s capability to acquire compensation for its new assessments at ranges just like its present assessments; dangers associated to elevated competitors and the event of recent competitors assessments and providers; The danger that the corporate won’t be able to develop or obtain industrial success for added molecular diagnostic assessments in a well timed method, or in any respect; The danger that the Firm won’t achieve creating new markets for its molecular diagnostic assessments, together with the Firm’s capability to generate profitable income outdoors america; the chance that licenses for the know-how underlying the Firm’s molecular diagnostics assessments and any future assessments could also be terminated or can’t be held on passable phrases; Dangers associated to delays or different issues associated to the operation and building of the Firm’s laboratory testing amenities; Dangers associated to public concern about genetic testing basically or firm testing specifically; dangers associated to regulatory or enforcement necessities in america and overseas nations and adjustments within the construction of the well being care system or well being care cost techniques; Dangers associated to the Firm’s capability to amass new licenses or institutional collaborations and to amass or develop new applied sciences or companies on passable phrases, if any; Dangers associated to the Firm’s capability to efficiently combine and profit from any applied sciences or companies it licenses, acquires or develops; Dangers associated to the Firm’s expectations about potential market alternatives for the Firm’s present and future merchandise; the chance that the Firm or its licensors won’t be able to guard it or that third events will violate the proprietary methods upon which the Firm’s assessments are based mostly; the chance of claims of patent infringement or challenges to the validity of the corporate’s patents; Dangers associated to adjustments in mental property legal guidelines masking the corporate’s molecular diagnostic assessments, patents or enforcement, in america and overseas nations; dangers associated to safety breaches, knowledge loss and different disruptions, together with cyber assaults; the dangers of recent, altering, and aggressive applied sciences and rules in america and internationally; the chance of the Firm’s lack of ability to adjust to its monetary working covenants underneath the Firm’s credit score or lending agreements; Dangers associated to materials weak point associated to normal IT controls, together with their impression and the Firm’s remedial plan, and its capability to attain and keep efficient disclosure controls and procedures and inside management over monetary reporting; dangers associated to present and future litigation, together with skilled or product legal responsibility claims; and different elements mentioned underneath “Danger Components” in Part 1A of the Firm’s Annual Report on Kind 10-Ok filed with the Securities and Trade Fee on February 25, 2022, in addition to any updates to those danger elements supplied every now and then specified within the firm’s quarterly reviews on Kind 10-Q or present reviews on Kind 8-Ok. The reported variety of medical doctors and sufferers within the Epic community was supplied by Epic.

Media contact:
Megan Manzari
(385) 318-3718

Investor contact:
Nathan Smith
(801) 505-5067